# COMETA THERAPEUTICS INC: ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | COMETA THERAPEUTICS INC |
| Location | TOWSON, MD |
| Project | ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b |
| Project number | 4R42DK141304-02 |
| Mechanism | R42 |
| Institute | National Institute of Diabetes and Digestive and Kidney Diseases |
| Award | $845,383 |
| Awarded | 2026-08-27 |
| Project period | 2025-06-01 to 2028-08-31 |
| UEI | RNTBQE96PX23 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11467059). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.